MyShare
Key factors
| sym | EVFM |
| exch | US |
| MCap | 170.07K |
| Beta | -1.19 |
| PE Ratio | 0.4th |
| EPS | 38.97 |
| Div date | 0000-00-00 |
Yesterday
| sym | EVFM |
| exch | US |
| close | 0.014 |
| 50 Day MA | 0.022 |
| 200 Day MA | 0.163 |
| 52 Week High | 4.375 |
| 52 Week Low | 0.012 |
| Target Price | 225.0 |
| Market Cap Mln | 0.170 |
Share statistics
| Shares Outstanding | 10.73M |
| Shares Float | 10.72M |
| Percent Institutions | 0.958 |
| PercentInsiders | 0.014 |
| SharesShort | 8682.85K |
| Short Ratio | 0.19 |
| Shares Short Prior Month | 10.99M |
| Short Percent | 11.01 |
Income
| Revenue TTM | 13.56M |
| Revenue Per Share TTM | 6.404 |
| Quarterly Revenue Growth YOY | -19.7 |
| Gross Profit TTM | 12.42M |
| EBITDA | -25.8M |
| Diluted Eps TTM | 38.97 |
earning
| Operating Margin TTM | -0.69 |
| Trailing PE | 0.4th |
| Earnings Share | 38.97 |
Dividend
| Dividend Date | 2018-01-18 |
| Last Split Date | 2023-05-18 |
| Last Split Factor | 1:125 |
business
| Enterprise Value Ebitda | -2.74 |
| Enterprise Value Revenue | 2.420 |
| Book Value /share | -9.92 |
| Price Book MRQ | 8.372 |
| Price Sales TTM | 0.012 |
| ProfitMargin | 3.448 |
| ReturnOnAssetsTTM | -0.59 |
| ReturnOnEquityTTM | -3.87 |
Sector
| Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry | Pharmaceuticals |
| Gic Sector | Health Care |
| Industry | Biotechnology |
| Sector | Healthcare |
Codes
| ISIN | US30048L2034 |
| CIK | 1618835 |
| Code | EVFM |
| CUSIP | 30048L104 |
| CountryISO | US |
| Currency Code | USD |
| Currency Name | US Dollar |
| Exchange | OTCQB |
| Currency Symbol | $ |
fund
| Type | Common Stock |
| UpdatedAt | 2024-04-12 |
| Home Category | Domestic |
info
| Fiscal Year End | December |
| Full Time Employees | 35.0 |
| IPODate | 2018-01-17 |
| MostRecent Quarter | 2023-12-31 |
Contact
| Name | Evofem Biosciences Inc |
| Address | 7770 Regents Roas, San Diego, CA, United States, 92122 |
| Country Name | USA |
| Phone | 858 550 1900 |
| Web URL | https://www.evofem.com |
| Logo URL | /img/logos/US/EVFM.png |
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.